Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Nov;79(937):634–642. doi: 10.1136/pmj.79.937.634

Drug therapy in chronic heart failure

D McKenzie 1, A Cowley 1
PMCID: PMC1742875  PMID: 14654574

Full Text

The Full Text of this article is available as a PDF (394.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17–22. doi: 10.1136/hrt.57.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berry C., Murdoch D. R., McMurray J. J. Economics of chronic heart failure. Eur J Heart Fail. 2001 Jun;3(3):283–291. doi: 10.1016/s1388-9842(01)00123-4. [DOI] [PubMed] [Google Scholar]
  3. Blue L., Lang E., McMurray J. J., Davie A. P., McDonagh T. A., Murdoch D. R., Petrie M. C., Connolly E., Norrie J., Round C. E. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ. 2001 Sep 29;323(7315):715–718. doi: 10.1136/bmj.323.7315.715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cleland J. G., Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet. 1998 May 30;351(9116):1657–1658. doi: 10.1016/s0140-6736(05)77712-6. [DOI] [PubMed] [Google Scholar]
  5. Cohn J. N., Archibald D. G., Ziesche S., Franciosa J. A., Harston W. E., Tristani F. E., Dunkman W. B., Jacobs W., Francis G. S., Flohr K. H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. doi: 10.1056/NEJM198606123142404. [DOI] [PubMed] [Google Scholar]
  6. Cohn J. N., Goldstein S. O., Greenberg B. H., Lorell B. H., Bourge R. C., Jaski B. E., Gottlieb S. O., McGrew F., 3rd, DeMets D. L., White B. G. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998 Dec 17;339(25):1810–1816. doi: 10.1056/NEJM199812173392503. [DOI] [PubMed] [Google Scholar]
  7. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  8. Cohn J. N., Tognoni G., Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6;345(23):1667–1675. doi: 10.1056/NEJMoa010713. [DOI] [PubMed] [Google Scholar]
  9. Cohn J. N., Ziesche S., Smith R., Anand I., Dunkman W. B., Loeb H., Cintron G., Boden W., Baruch L., Rochin P. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997 Aug 5;96(3):856–863. doi: 10.1161/01.cir.96.3.856. [DOI] [PubMed] [Google Scholar]
  10. Cohn Jay N. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am J Cardiol. 2002 Nov 1;90(9):992–993. doi: 10.1016/s0002-9149(02)02667-x. [DOI] [PubMed] [Google Scholar]
  11. Cowburn P. J., Cleland J. G., McArthur J. D., MacLean M. R., McMurray J. J., Dargie H. J. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet. 1998 Jul 18;352(9123):201–202. doi: 10.1016/S0140-6736(05)77807-7. [DOI] [PubMed] [Google Scholar]
  12. Cowie M. R., Wood D. A., Coats A. J., Thompson S. G., Poole-Wilson P. A., Suresh V., Sutton G. C. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999 Mar;20(6):421–428. doi: 10.1053/euhj.1998.1280. [DOI] [PubMed] [Google Scholar]
  13. Cowley A. J., Skene A. M. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Br Heart J. 1994 Sep;72(3):226–230. doi: 10.1136/hrt.72.3.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dickstein K., Chang P., Willenheimer R., Haunsø S., Remes J., Hall C., Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995 Aug;26(2):438–445. doi: 10.1016/0735-1097(95)80020-h. [DOI] [PubMed] [Google Scholar]
  15. Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol. 1999 Feb 15;83(4):477–481. doi: 10.1016/s0002-9149(98)00898-4. [DOI] [PubMed] [Google Scholar]
  16. Doval H. C., Nul D. R., Grancelli H. O., Perrone S. V., Bortman G. R., Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Lancet. 1994 Aug 20;344(8921):493–498. doi: 10.1016/s0140-6736(94)91895-3. [DOI] [PubMed] [Google Scholar]
  17. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991 Aug 1;325(5):293–302. doi: 10.1056/NEJM199108013250501. [DOI] [PubMed] [Google Scholar]
  18. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987 Jun 4;316(23):1429–1435. doi: 10.1056/NEJM198706043162301. [DOI] [PubMed] [Google Scholar]
  19. Eichhorn E. J., Bristow M. R. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997 Mar 15;79(6):794–798. doi: 10.1016/s0002-9149(96)00873-9. [DOI] [PubMed] [Google Scholar]
  20. Feldman A. M., Combes A., Wagner D., Kadakomi T., Kubota T., Li Y. Y., McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000 Mar 1;35(3):537–544. doi: 10.1016/s0735-1097(99)00600-2. [DOI] [PubMed] [Google Scholar]
  21. Francis G. S., Goldsmith S. R., Cohn J. N. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J. 1982 Oct;104(4 Pt 1):725–731. doi: 10.1016/0002-8703(82)90003-5. [DOI] [PubMed] [Google Scholar]
  22. Frishman W. H. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation. 1983 Jun;67(6 Pt 2):I11–I18. [PubMed] [Google Scholar]
  23. Galatius-Jensen S., Wroblewski H., Emmeluth C., Bie P., Haunsø S., Kastrup J. Plasma endothelin in congestive heart failure: a predictor of cardiac death? J Card Fail. 1996 Jun;2(2):71–76. doi: 10.1016/s1071-9164(96)80025-x. [DOI] [PubMed] [Google Scholar]
  24. Givertz M. M., Colucci W. S., LeJemtel T. H., Gottlieb S. S., Hare J. M., Slawsky M. T., Leier C. V., Loh E., Nicklas J. M., Lewis B. E. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000 Jun 27;101(25):2922–2927. doi: 10.1161/01.cir.101.25.2922. [DOI] [PubMed] [Google Scholar]
  25. Hampton J. R., van Veldhuisen D. J., Kleber F. X., Cowley A. J., Ardia A., Block P., Cortina A., Cserhalmi L., Follath F., Jensen G. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997 Apr 5;349(9057):971–977. doi: 10.1016/s0140-6736(96)10488-8. [DOI] [PubMed] [Google Scholar]
  26. Ho K. K., Anderson K. M., Kannel W. B., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993 Jul;88(1):107–115. doi: 10.1161/01.cir.88.1.107. [DOI] [PubMed] [Google Scholar]
  27. Houghton A. R., Cowley A. J. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol. 1997 Mar;59(1):7–10. doi: 10.1016/s0167-5273(96)02904-x. [DOI] [PubMed] [Google Scholar]
  28. Kaddoura S., Patel D., Parameshwar J., Sparrow J., Park A., Bayliss J., Sutton G. C., Poole-Wilson P. A. Objective assessment of the response to treatment of severe heart failure using a 9-minute walk test on a patient-powered treadmill. J Card Fail. 1996 Jun;2(2):133–139. doi: 10.1016/s1071-9164(96)80032-7. [DOI] [PubMed] [Google Scholar]
  29. Kalra Paul R., Moon James C. C., Coats Andrew J. S. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002 Oct;85(2-3):195–197. doi: 10.1016/s0167-5273(02)00182-1. [DOI] [PubMed] [Google Scholar]
  30. Kiowski W., Sütsch G., Hunziker P., Müller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995 Sep 16;346(8977):732–736. doi: 10.1016/s0140-6736(95)91504-4. [DOI] [PubMed] [Google Scholar]
  31. Kjekshus J., Pedersen T. R., Olsson A. G., Faergeman O., Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997 Dec;3(4):249–254. doi: 10.1016/s1071-9164(97)90022-1. [DOI] [PubMed] [Google Scholar]
  32. Køber L., Torp-Pedersen C., Carlsen J. E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D. S., Auclert L., Pauly N. C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec 21;333(25):1670–1676. doi: 10.1056/NEJM199512213332503. [DOI] [PubMed] [Google Scholar]
  33. Lang R. M., Elkayam U., Yellen L. G., Krauss D., McKelvie R. S., Vaughan D. E., Ney D. E., Makris L., Chang P. I. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol. 1997 Oct;30(4):983–991. doi: 10.1016/s0735-1097(97)00253-2. [DOI] [PubMed] [Google Scholar]
  34. Love M. P., McMurray J. J. Endothelin in heart failure: a promising therapeutic target? Heart. 1997 Feb;77(2):93–94. doi: 10.1136/hrt.77.2.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mann D. L., Kent R. L., Parsons B., Cooper G., 4th Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992 Feb;85(2):790–804. doi: 10.1161/01.cir.85.2.790. [DOI] [PubMed] [Google Scholar]
  36. McClean D. R., Ikram H., Garlick A. H., Richards A. M., Nicholls M. G., Crozier I. G. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000 Aug;36(2):479–486. doi: 10.1016/s0735-1097(00)00741-5. [DOI] [PubMed] [Google Scholar]
  37. McMurray J. J., Ray S. G., Abdullah I., Dargie H. J., Morton J. J. Plasma endothelin in chronic heart failure. Circulation. 1992 Apr;85(4):1374–1379. doi: 10.1161/01.cir.85.4.1374. [DOI] [PubMed] [Google Scholar]
  38. McMurray J. J., Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000 May;83(5):596–602. doi: 10.1136/heart.83.5.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. McMurray J., Cohen-Solal A., Dietz R., Eichhorn E., Erhardt L., Hobbs R., Maggioni A., Pina I., Soler-Soler J., Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail. 2001 Aug;3(4):495–502. doi: 10.1016/s1388-9842(01)00173-8. [DOI] [PubMed] [Google Scholar]
  40. McMurray J., Cohen-Solal A., Dietz R., Eichhorn E., Erhardt L., Hobbs R., Maggioni A., Pina I., Soler-Soler J., Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail. 2001 Aug;3(4):495–502. doi: 10.1016/s1388-9842(01)00173-8. [DOI] [PubMed] [Google Scholar]
  41. McMurray J. Heart failure: we need more trials in typical patients. Eur Heart J. 2000 May;21(9):699–700. doi: 10.1053/euhj.1999.1974. [DOI] [PubMed] [Google Scholar]
  42. McMurray J. Heart failure: we need more trials in typical patients. Eur Heart J. 2000 May;21(9):699–700. doi: 10.1053/euhj.1999.1974. [DOI] [PubMed] [Google Scholar]
  43. Northridge D. B., Currie P. F., Newby D. E., McMurray J. J., Ford M., Boon N. A., Dargie H. J. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail. 1999 Mar;1(1):67–72. doi: 10.1016/S1388-9842(98)00003-8. [DOI] [PubMed] [Google Scholar]
  44. Northridge D. B., Jardine A. G., Alabaster C. T., Barclay P. L., Connell J. M., Dargie H. J., Dilly S. G., Findlay I. N., Lever A. F., Samuels G. M. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet. 1989 Sep 9;2(8663):591–593. doi: 10.1016/s0140-6736(89)90714-9. [DOI] [PubMed] [Google Scholar]
  45. Packer M., Bristow M. R., Cohn J. N., Colucci W. S., Fowler M. B., Gilbert E. M., Shusterman N. H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349–1355. doi: 10.1056/NEJM199605233342101. [DOI] [PubMed] [Google Scholar]
  46. Packer M., Carver J. R., Rodeheffer R. J., Ivanhoe R. J., DiBianco R., Zeldis S. M., Hendrix G. H., Bommer W. J., Elkayam U., Kukin M. L. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991 Nov 21;325(21):1468–1475. doi: 10.1056/NEJM199111213252103. [DOI] [PubMed] [Google Scholar]
  47. Packer M., Coats A. J., Fowler M. B., Katus H. A., Krum H., Mohacsi P., Rouleau J. L., Tendera M., Castaigne A., Roecker E. B. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651–1658. doi: 10.1056/NEJM200105313442201. [DOI] [PubMed] [Google Scholar]
  48. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med. 2001 May 7;110 (Suppl 7A):81S–94S. doi: 10.1016/s0002-9343(01)00676-3. [DOI] [PubMed] [Google Scholar]
  49. Packer M., Gheorghiade M., Young J. B., Costantini P. J., Adams K. F., Cody R. J., Smith L. K., Van Voorhees L., Gourley L. A., Jolly M. K. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993 Jul 1;329(1):1–7. doi: 10.1056/NEJM199307013290101. [DOI] [PubMed] [Google Scholar]
  50. Packer M., O'Connor C. M., Ghali J. K., Pressler M. L., Carson P. E., Belkin R. N., Miller A. B., Neuberg G. W., Frid D., Wertheimer J. H. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996 Oct 10;335(15):1107–1114. doi: 10.1056/NEJM199610103351504. [DOI] [PubMed] [Google Scholar]
  51. Packer M., Poole-Wilson P. A., Armstrong P. W., Cleland J. G., Horowitz J. D., Massie B. M., Rydén L., Thygesen K., Uretsky B. F. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999 Dec 7;100(23):2312–2318. doi: 10.1161/01.cir.100.23.2312. [DOI] [PubMed] [Google Scholar]
  52. Packer Milton, Califf Robert M., Konstam Marvin A., Krum Henry, McMurray John J., Rouleau Jean-Lucien, Swedberg Karl. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002 Aug 20;106(8):920–926. doi: 10.1161/01.cir.0000029801.86489.50. [DOI] [PubMed] [Google Scholar]
  53. Petrie M. C., McClure S. J., Love M. P., McMurray J. J. Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. Eur J Heart Fail. 1999 Mar;1(1):25–29. doi: 10.1016/S1388-9842(98)00013-0. [DOI] [PubMed] [Google Scholar]
  54. Petrie M. C., Padmanabhan N., McDonald J. E., Hillier C., Connell J. M., McMurray J. J. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol. 2001 Mar 15;37(4):1056–1061. doi: 10.1016/s0735-1097(01)01111-1. [DOI] [PubMed] [Google Scholar]
  55. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  56. Pitt B., Poole-Wilson P. A., Segal R., Martinez F. A., Dickstein K., Camm A. J., Konstam M. A., Riegger G., Klinger G. H., Neaton J. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 May 6;355(9215):1582–1587. doi: 10.1016/s0140-6736(00)02213-3. [DOI] [PubMed] [Google Scholar]
  57. Pitt B., Segal R., Martinez F. A., Meurers G., Cowley A. J., Thomas I., Deedwania P. C., Ney D. E., Snavely D. B., Chang P. I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet. 1997 Mar 15;349(9054):747–752. doi: 10.1016/s0140-6736(97)01187-2. [DOI] [PubMed] [Google Scholar]
  58. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  59. Remme W. J., Swedberg K., Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001 Sep;22(17):1527–1560. doi: 10.1053/euhj.2001.2783. [DOI] [PubMed] [Google Scholar]
  60. Remme W. J., Swedberg K., Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001 Sep;22(17):1527–1560. doi: 10.1053/euhj.2001.2783. [DOI] [PubMed] [Google Scholar]
  61. Rich M. W., Beckham V., Wittenberg C., Leven C. L., Freedland K. E., Carney R. M. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995 Nov 2;333(18):1190–1195. doi: 10.1056/NEJM199511023331806. [DOI] [PubMed] [Google Scholar]
  62. Richardson L. G., Rocks M. Women and heart failure. Heart Lung. 2001 Mar-Apr;30(2):87–97. doi: 10.1067/mhl.2001.114191. [DOI] [PubMed] [Google Scholar]
  63. Rouleau J. L., Pfeffer M. A., Stewart D. J., Isaac D., Sestier F., Kerut E. K., Porter C. B., Proulx G., Qian C., Block A. J. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000 Aug 19;356(9230):615–620. doi: 10.1016/s0140-6736(00)02602-7. [DOI] [PubMed] [Google Scholar]
  64. Sackner-Bernstein J. D., Mancini D. M. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA. 1995 Nov 8;274(18):1462–1467. [PubMed] [Google Scholar]
  65. Silverberg D. S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., Schwartz D., Yachnin T., Steinbruch S., Shapira I. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001 Jun 1;37(7):1775–1780. doi: 10.1016/s0735-1097(01)01248-7. [DOI] [PubMed] [Google Scholar]
  66. Stewart S., Marley J. E., Horowitz J. D. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet. 1999 Sep 25;354(9184):1077–1083. doi: 10.1016/s0140-6736(99)03428-5. [DOI] [PubMed] [Google Scholar]
  67. Taylor S. H. Refocus on diuretics in the treatment of heart failure. Eur Heart J. 1995 Jul;16 (Suppl F):7–15. doi: 10.1093/eurheartj/16.suppl_f.7. [DOI] [PubMed] [Google Scholar]
  68. Torp-Pedersen C., Møller M., Bloch-Thomsen P. E., Køber L., Sandøe E., Egstrup K., Agner E., Carlsen J., Videbaek J., Marchant B. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999 Sep 16;341(12):857–865. doi: 10.1056/NEJM199909163411201. [DOI] [PubMed] [Google Scholar]
  69. Torre-Amione G., Young J. B., Durand J., Bozkurt B., Mann D. L., Kobrin I., Pratt C. M. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001 Feb 20;103(7):973–980. doi: 10.1161/01.cir.103.7.973. [DOI] [PubMed] [Google Scholar]
  70. Tsuyuki R. T., Yusuf S., Rouleau J. L., Maggioni A. P., McKelvie R. S., Wiecek E. M., Wang Y., Pogue J., Teo K. K., White M. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol. 1997 Dec;13(12):1166–1174. [PubMed] [Google Scholar]
  71. Udelson J. E., Smith W. B., Hendrix G. H., Painchaud C. A., Ghazzi M., Thomas I., Ghali J. K., Selaru P., Chanoine F., Pressler M. L. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417–2423. doi: 10.1161/hc4501.099313. [DOI] [PubMed] [Google Scholar]
  72. Uretsky B. F., Young J. B., Shahidi F. E., Yellen L. G., Harrison M. C., Jolly M. K. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993 Oct;22(4):955–962. doi: 10.1016/0735-1097(93)90403-n. [DOI] [PubMed] [Google Scholar]
  73. Varela-Roman A., Gonzalez-Juanatey J. R., Basante P., Trillo R., Garcia-Seara J., Martinez-Sande J. L., Gude F. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart. 2002 Sep;88(3):249–254. doi: 10.1136/heart.88.3.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Vasan R. S., Larson M. G., Benjamin E. J., Evans J. C., Reiss C. K., Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999 Jun;33(7):1948–1955. doi: 10.1016/s0735-1097(99)00118-7. [DOI] [PubMed] [Google Scholar]
  75. Viquerat C. E., Daly P., Swedberg K., Evers C., Curran D., Parmley W. W., Chatterjee K. Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med. 1985 Mar;78(3):455–460. doi: 10.1016/0002-9343(85)90338-9. [DOI] [PubMed] [Google Scholar]
  76. Waagstein F., Bristow M. R., Swedberg K., Camerini F., Fowler M. B., Silver M. A., Gilbert E. M., Johnson M. R., Goss F. G., Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11;342(8885):1441–1446. doi: 10.1016/0140-6736(93)92930-r. [DOI] [PubMed] [Google Scholar]
  77. Walker S., Levy T. M., Coats A. J., Peters N. S., Paul V. E. Bi-ventricular pacing in congestive cardiac failure. Current experience and future directions. The Imperial College Cardiac Electrophysiology Group. Eur Heart J. 2000 Jun;21(11):884–889. doi: 10.1053/euhj.1999.1913. [DOI] [PubMed] [Google Scholar]
  78. Wolny A., Clozel J. P., Rein J., Mory P., Vogt P., Turino M., Kiowski W., Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997 Feb;80(2):219–227. doi: 10.1161/01.res.80.2.219. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES